FDAnews
FDAnews Drug Daily Bulletin

AFFECTIS PHARMACEUTICALS AG ANNOUNCES TARGET VALIDATION COLLABORATION WITH ORGANON

Nov. 3, 2005

Affectis Pharmaceuticals AG and Organon, the human healthcare business unit of Akzo Nobel, have entered into a collaboration by which Affectis will apply its pioneering target validation technology and its exclusive preclinical models for the validation of Organon's gene targets involved in depression and anxiety. Today, one of the major challenges in developing optimised drugs against affective disorders is the limited availability of suitable preclinical models and sufficient expertise in selecting promising targets and leads as well as their preclinical development.
Biotech Intelligence